Content |
Assets
Sobi is an international rare disease company that aims to provide access to modern treatments that significantly affect people with rare diseases.
History
2023: Orphan Biovitrum buys CTI BioPharma for $1.7 billion
On May 10, 2023, the Swedish pharmaceutical company Swedish Orphan Biovitrum (Sobi) announced the conclusion of an agreement on the acquisition of the American CTI BioPharma. The transaction amount will be $1.7 billion in cash. Read more here.
2019: Plans to buy Dova Pharmaceuticals
On October 1, 2019, it became known that the Swedish pharmaceutical company Swedish Orphan Biovitrum (Swedish Orphan Biovitrum, Sobi), specializing in the development of drugs for the treatment of rare diseases, announced the acquisition. the American Dova Pharmaceuticals More. here
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |